03.07.2013 Views

Conference Sessions - Jesse H. Jones Graduate School of ...

Conference Sessions - Jesse H. Jones Graduate School of ...

Conference Sessions - Jesse H. Jones Graduate School of ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

SB09<br />

■ SB09<br />

Founders III<br />

International Marketing I: General/Emerging Markets<br />

Contributed Session<br />

Chair: Sameer Mathur, Assistant Pr<strong>of</strong>essor, McGill University,<br />

1001 Sherbrooke West, Montreal, QC, H3A, Canada,<br />

sameer.mathur@mcgill.ca<br />

1 - Global Expansion to vs. from Emerging Markets: An Empirical Study<br />

<strong>of</strong> Cross-border M & A’s Completion<br />

Chenxi Zhou, University <strong>of</strong> Florida, Marketing Department, P.O. Box<br />

117155, Gainesville, FL, 326117155, United States <strong>of</strong> America,<br />

chenxi.zhou@warrington.ufl.edu, Qi Wang, Jinhong Xie<br />

While multinational companies have long been expanding into emerging markets, in<br />

recent years companies based in emerging markets have started to expand abroad.<br />

This new trend imposes challenges to global marketers and raises new issues for<br />

marketing scholars.This study investigates how the direction <strong>of</strong> global expansion:TO<br />

vs.FROM emerging markets, may affect the determinants <strong>of</strong> the completion<br />

probability <strong>of</strong> announced cross-border mergers and acquisition. Specifically, we<br />

empirically compare two types <strong>of</strong> cross-border M&As: (1) In-Bound, in which a firm<br />

from a developed economy acquires a firm in an emerging economy, and (2) Out-<br />

Bound, in which a firm from an emerging economy acquires a firm in a developed<br />

economy. Using data collected from the two largest emerging markets, China and<br />

India, from 1980 to 2009, our empirical analyses reveal some fundamental<br />

differences between the two types <strong>of</strong> cross-border M&As. For example, country-level<br />

factors, which measure the differences between the two countries involved (e.g.,<br />

difference in political, trade, and legal environment), are the most influential factors<br />

for the successful completion <strong>of</strong> In-Bound M&As. However, firm-level factors, which<br />

measure the acquirer’s capability (e.g., firm size and experience), are the most<br />

influential factors for the completion <strong>of</strong> Out-Bound M&As. Furthermore, deal-level<br />

factors, which measure characteristics <strong>of</strong> the specific transaction (e.g.,percentage <strong>of</strong><br />

stake sought by the acquirer, whether the deal size is disclosed, and whether the deal<br />

is paid by cash), have differential effects on the two types <strong>of</strong> M&As. These findings<br />

provide important managerial implications to global marketers on how to enhance<br />

the success <strong>of</strong> global expansions.<br />

2 - Going Global: Why Some Firms from Emerging Markets<br />

Internationalize More than Others<br />

Sourindra Banerjee, University <strong>of</strong> Cambridge, 2360 Portland Street,<br />

Los Angeles, CA, 90007, United States <strong>of</strong> America,<br />

sourindrab@gmail.com, Rajesh Chandy, Jaideep Prabhu<br />

The recent rapid internationalization <strong>of</strong> firms from emerging markets has generated a<br />

great deal <strong>of</strong> interest among academics and practitioners alike. How do emerging<br />

market firms which lack foreign market knowledge, have inadequate financial<br />

resources and have weak institutional support in their home countries achieve such<br />

remarkable global expansion? In this paper we argue that a top management team<br />

member with international education and international experience play the role <strong>of</strong> a<br />

strategic actor who helps emerging market firms overcome their lack <strong>of</strong> foreign<br />

market knowledge. Further, we propose that emerging market firms surmount their<br />

inadequate financial strength by accessing international financial resources and<br />

circumvent their weak institutional environment through their affiliation with a<br />

business group. We test our hypotheses using uniquely compiled data on 173nonstate<br />

owned Indian firms from the Bombay Stock Exchange 500 index. Our results<br />

provide broad support for our thesis and <strong>of</strong>fer important implications for research and<br />

practice alike.<br />

3 - Multinational Strategic Alliance Models between Taiwan and China<br />

Shih-Wei Huang, National Taiwan Normal University, 5F., No.256,<br />

Sec. 1, Heping E. Rd., Taipei, 106, Taiwan - ROC,<br />

hc22933w@yahoo.com.tw, Wun-Hwa Chen, Ai-Hsuan Chiang<br />

In the globalization competition environment, it seems hard for firms to use only<br />

their own resources to seek breakthrough in technology and marketing. We have<br />

found strategic alliance become a strategies for enterprises from multiple countries to<br />

share resources, co-develop technologies, learn important skills, enhance their<br />

competitive position, and then achieve the synergy effect. With increasing<br />

environmental awareness, the green energy industry such as LED attracted much<br />

attention from both managers and researchers. Our research will interviews with<br />

senior managers in Taiwan LED industries. We discuss how Taiwan and China<br />

enterprises form strategic alliance to integrate the supply chain, uniform standards,<br />

acquire technology, gain knowledge and then co-develop products and then entry<br />

into new markets.<br />

4 - Quantity Discounts in Emerging Markets<br />

Sameer Mathur, Assistant Pr<strong>of</strong>essor, McGill University,<br />

1001 Sherbrooke West, Montreal, QC, H3A, Canada,<br />

sameer.mathur@mcgill.ca, Kannan Srinivasan, Preyas Desai<br />

Emerging markets like China and India are becoming dominant in the global<br />

economy. This paper contrasts the quantity discount decisions make by competing<br />

firms in such markets to the quantity decisions made in developed markets such as<br />

the United States. Anecdotal evidence indicates that while high-quality firms like<br />

Dove <strong>of</strong>fer a larger quantity discount than comparatively low-quality firms like<br />

Garnier Fructis in the United States, the trend in opposite in India. This paper uses<br />

equilibrium analysis to explain why such a reversal in firm strategy in emerging<br />

MARKETING SCIENCE CONFERENCE – 2011<br />

84<br />

markets is optimal. Emerging markets have a larger proportion <strong>of</strong> cash-constrained<br />

consumers with limited ability-to-pay, compared to developed markets. In order to<br />

sell to such consumers in emerging markets, firms reset the prices <strong>of</strong> their smaller,<br />

comparatively cheaper package sizes. At equilibrium, this distortion in prices <strong>of</strong> small<br />

package sizes causes a reversal in relative quantity discounts <strong>of</strong>fered by the firms. A<br />

limited field survey <strong>of</strong> Indian and American markets lends support to our theoretical<br />

findings.<br />

■ SB10<br />

Founders IV<br />

Health Care Marketing II<br />

Cluster: Special <strong>Sessions</strong><br />

Invited Session<br />

Chair: Jaap Wieringa, Associate Pr<strong>of</strong>essor, University <strong>of</strong> Groningen,<br />

Groningen, Netherlands, j.e.wieringa@rug.nl<br />

Chair: Philip Stern, Pr<strong>of</strong>essor, Loughborough University,<br />

Loughborough University, United Kingdom, P.Stern@lboro.ac.uk<br />

1 - Product Bundling in Patent-protected Markets<br />

Eelco Kappe, Erasmus University Rotterdam, Erasmus <strong>School</strong> <strong>of</strong><br />

Economics (ESE), Erasmus, Netherlands, kappe@ese.eur.nl,<br />

Stefan Stremersch<br />

What is the effect <strong>of</strong> product bundles in patent-protected markets? Combination<br />

drugs are an example <strong>of</strong> such a product bundle and have become a very popular<br />

method <strong>of</strong> extending the life cycle <strong>of</strong> drugs that lose patent protection. We<br />

disentangle the effects <strong>of</strong> introducing a combination drug (a combination <strong>of</strong> two<br />

molecules into one drug) on its components and the market, i.e. cannibalization vs.<br />

market expansion. Empirically, we investigate how the price and promotion <strong>of</strong> the<br />

bundle impact its components and vice versa. We also compare this to optimal<br />

promotion and pricing strategies under different organizational forms, like product<br />

management and category management. Using unique data on over 100 combination<br />

drugs in the pharmaceutical industry, we assess how these effects differ over drugs.<br />

The model allows for heterogeneous effects and corrects for the price and<br />

promotional endogeneity.<br />

2 - How Generic Drugs Affect Brands Before and After Entry<br />

Jaap Wieringa, Associate Pr<strong>of</strong>essor, University <strong>of</strong> Groningen,<br />

Groningen, Netherlands, j.e.wieringa@rug.nl, Peter Leeflang,<br />

Ernst Osinga<br />

The expiration <strong>of</strong> patents on branded drugs opens the door for lower priced generic<br />

products based on the same molecule. Typically, the combined sales <strong>of</strong> the branded<br />

and the generic product, i.e. total molecule sales, are lower after patent expiration<br />

than before. This decline has been hypothesized to follow from a reduction in<br />

marketing expenditures for the molecule, starting far ahead <strong>of</strong> patent expiration.<br />

Despite its importance, as far as we are aware <strong>of</strong>, no study has empirically tested the<br />

dynamics that are inherent to the introduction <strong>of</strong> a generic. We consider dynamics in<br />

the time period before and after the introduction <strong>of</strong> the generic. Relying on a<br />

nonlinear state space model in combination with importance-sampling based<br />

estimation, we analyze two major brands that went <strong>of</strong>f-patent in 1997 and show that<br />

generic sales’ increases fully go at the cost <strong>of</strong> the corresponding brands. We conclude<br />

that the reduction in the brand’s marketing expenditures towards patent expiration is<br />

in line with an appropriate allocation <strong>of</strong> marketing expenditures on the long run.<br />

Through a simulation experiment we show that continued spending on marketing<br />

leads to higher molecule sales. Depending on the assumption one makes about the<br />

amount <strong>of</strong> marketing expenditures needed to <strong>of</strong>fset competing brands’ marketing<br />

expenditures, we find that continued marketing expenditures may create cost savings<br />

for society.<br />

3 - How, When and to Whom Should Pharmaceutical Innovations<br />

be Promoted?<br />

Katrin Reber, University <strong>of</strong> Groningen, Groningen, Netherlands,<br />

k.reber@rug.nl, Peter Leeflang, Philip Stern, Jaap Wieringa<br />

Pharmaceutical companies continually launch new drugs into the marketplace, and<br />

for these drugs, timely adoption by and diffusion across physicians is crucial to<br />

commercial success and the ability to recover the high and risky investments. In this<br />

study we investigate what marketing strategies are effective to ensure the successful<br />

market introduction <strong>of</strong> new drugs, and how marketing response varies by productrelated,<br />

decision-maker-related, and time-varying factors. Combining these three<br />

dimensions simultaneously we provide a broader picture <strong>of</strong> how these factors jointly<br />

influence the effectiveness <strong>of</strong> marketing communication. This helps understanding<br />

why and how new products are accepted differently, and may provide guidelines for<br />

managers regarding (1) the introduction <strong>of</strong> other innovations in the same category,<br />

and (2) the improvement <strong>of</strong> marketing resource allocation across products,<br />

physicians, and time. For our empirical analyses we have access to the complete<br />

prescription history <strong>of</strong> a panel <strong>of</strong> 1505 UK-based physicians over 23 year. We also<br />

have information on the detailing history <strong>of</strong> each <strong>of</strong> the physicians as well as on<br />

various physician characteristics. We base our analyses on a four-segment-trial-repeat<br />

model where we consider a time-dependent Marckovian structure for the transition<br />

probabilities. To accommodate physician and product heterogeneity in the model a<br />

hierarchical Bayesian setup is followed.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!